|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.26 - 12:00
|
Gilead and PAHO agree to expedite lenacapavir access for HIV prevention (PBR)
|
|
|
The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries, including Argentina,
The post Gilead and PAHO agree to expedite lenacapavir access for HIV prevention appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
09.09.26 - 18:30
|
Assembly Biosciences zieht Milliarden-Option: Countdown auf den 15. Oktober gestartet (Sharedeals)
|
|
|
Bei Assembly Biosciences spitzt sich die Investmentstory deutlich zu. Mein Biotech-Favorit hat gegenüber seinem Pharmapartner Gilead seine Option ausgeübt, sich mit 40 Prozent an den US-Entwicklungskosten zu beteiligen und damit im Gegenzug 40 Prozent der US-Gewinne des Herpes-Programms zu vereinnahmen. Damit ist eine Neubewertung Assemblys überfällig – das beginnen auch immer mehr Wall-Street-Analysten zu erkennen. […]
The post Assembly Biosciences zieht Milliarden-Option: Countdown auf den 15. Oktober gestartet first appeared on sharedeals.de....
|
|
|
09.09.26 - 17:06
|
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner (Business Wire)
|
|
|
MENLO PARK, Calif.--(BUSINESS WIRE)--Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Merdad Parsey, M.D., Ph.D., to the investment team as an Executive Partner.
Dr. Parsey is an accomplished biopharmaceutical executive and physician-scientist with more than 25 years of experience spanning research, clinical development, regulatory approval, commercialization, portfolio strategy and company building across biotechnology, pharmaceutical companies and academic medicine. Throughout his career, he has contributed to the development, approval and launch of numerous medicines across therapeutic areas and modalities.
Prior to joining Sofinnova, Dr. Parsey served as Executive Vice President and Chief Medical Officer of Gilead Sciences, where he oversaw Clinical Development, Medical Affairs, Clinical Operations, Clinical Data Sciences, Clinical Pharmacology, Biomarkers, Portfolio Strategy and Management, Regulatory, Safety Sciences, and Quality and Compliance. He was resp...
|
|
|
09.09.26 - 12:48
|
Gilead launches research facility in US for new medicine development (PBR)
|
|
|
The new facility expands the company's capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based in California
The post Gilead launches research facility in US for new medicine development appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
04.09.26 - 22:06
|
McRae Industries, Inc. Dividend Declared (PR Newswire)
|
|
|
MOUNT GILEAD, N.C., Sept. 4, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Company's Class A and Class B Common Stock payable on October 1, 2026 to shareholders of record on September 17, 2026. View original......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
